The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
It turns out that glyobblastomas actually suppress parts of the immune system. So they they're kind of like growing in stealth and they activate, you know, molecules and cells in a in a cloak way that can't be recognized by immune cells anymore.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
And so if we can basically allow the tumors to be recognized by the immune system, that could be something that really unlocks therapy in the future, too.
It turns out that glyobblastoomas actually suppress parts of the immune system. So they they're kind of like growing in stealth and they activate, you know, molecules and cells in a in a cloak way that can't be recognized by immune cells anymore.
Whole-body MRI screening in healthy adults produces more incidentaloma harm than cancer-mortality benefit.
Starting colonoscopy screening at 45 (vs 50) prevents enough early-onset cancers to justify the population cost.
Multi-cancer liquid-biopsy tests like Galleri detect early cancers at a stage that meaningfully improves survival.